Result card

  • EFF14: Would the patient be willing to use the technology (uPA/PAI or Mammaprint or Oncotype test) again?
English

Would the patient be willing to use the technology (uPA/PAI or Mammaprint or Oncotype test) again?

Authors: Authors: Mirjana Huic, Narine Sahakyan, Gurleen Jhuti, Anna Panasiuk, Heike Raatz, Petra Schnell-Inderst, Katarzyna Sejbuk, Eva Turk, Marjetka Jelenc

Internal reviewers: Luciana Ballini, Patricia Harrington, Stefan Lange, Michelle O'Neill, Paolo Giorgo Rossi, Stefan Sauerland, Luca Vignatelli, Siw Waffenschmidt

Acknowledgments: Jayne Hickton (Information Specialist, NICE)

Two published articles on Oncotype DX test addressed the question “Would the patient be willing to use the technology again?”

A multicentre cross-sectional study was performed in the Netherlands using a questionnaire, and supplemented by retrospective medical chart review; in Richman et al. 2011{24} most outcome data are duplicates of those reported in Tzeng et al. 2010 {23}. Of 104 invited women (mainly lymph node-negative), 78 completed the survey and 77 were analysed. Most women (96%, 74/77) reported that they would have the test again if they had to decide today, and 95%, 73/77 would recommend the test to other women (Table 1 in Appendix 4).

Critical
Partially
Huic A et al. Result Card EFF14 In: Huic A et al. Clinical Effectiveness In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=113

References